GEOVAX LABS INC

NASDAQ: GOVX (GeoVax Labs, Inc.)

Kemas kini terakhir: 07 Jun, 9:52AM

1.12

0.03 (2.75%)

Penutupan Terdahulu 1.09
Buka 1.12
Jumlah Dagangan 273,722
Purata Dagangan (3B) 434,338
Modal Pasaran 17,016,832
Harga / Jualan (P/S) 1.30
Harga / Buku (P/B) 1.94
Julat 52 Minggu
0.730 (-34%) — 11.18 (898%)
Tarikh Pendapatan 4 Aug 2025 - 8 Aug 2025
Margin Operasi (TTM) -330.18%
EPS Cair (TTM) -2.80
Nisbah Semasa (MRQ) 2.55
Aliran Tunai Operasi (OCF TTM) -24.68 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -16.53 M
Pulangan Atas Aset (ROA TTM) -915.19%
Pulangan Atas Ekuiti (ROE TTM) -78,814.56%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menurun Menurun
Biotechnology (Global) Menurun Menurun
Stok GeoVax Labs, Inc. Menurun Menurun

AISkor Stockmoo

-0.4
Konsensus Penganalisis 1.0
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal -0.5
Purata -0.38

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
GOVX 17 M - - 1.94
CGON 2 B - - 2.81
CVAC 1 B - 5.80 1.61
ABCL 1 B - - 1.09
GHRS 932 M - - 2.55
ORIC 908 M - - 3.33

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax’s product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 0.42%
% Dimiliki oleh Institusi 7.72%
131.15131.1597.7097.7064.2564.2530.8030.80-2.65-2.65Harga Sasaran MedianQ2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
0.730 (-34%) — 11.18 (898%)
Julat Harga Sasaran
8.00 (614%) — 9.00 (703%)
Tinggi 9.00 (D. Boral Capital, 703.57%) Beli
Median 8.50 (658.93%)
Rendah 8.00 (HC Wainwright & Co., 614.29%) Beli
Purata 8.50 (658.93%)
Jumlah 2 Beli
Harga Purata @ Panggilan 1.11
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
D. Boral Capital 16 Jun 2025 9.00 (703.57%) Beli 1.32
02 May 2025 9.00 (703.57%) Beli 1.01
HC Wainwright & Co. 16 Apr 2025 8.00 (614.29%) Beli 0.902

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
03 Jul 2025 Pengumuman GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat
02 Jul 2025 Pengumuman GeoVax Responds to Growing Mpox Threat With Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives
01 Jul 2025 Pengumuman GeoVax to Raise Approximately $6 Million of Gross Proceeds in Public Offering
25 Jun 2025 Pengumuman GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection
24 Jun 2025 Pengumuman GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy
17 Jun 2025 Pengumuman GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting
16 Jun 2025 Pengumuman GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA
12 Jun 2025 Pengumuman GeoVax to Participate in BIO International Convention 2025
11 Jun 2025 Pengumuman GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency
10 Jun 2025 Pengumuman GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients
09 Jun 2025 Pengumuman GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia
04 Jun 2025 Pengumuman GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology
29 May 2025 Pengumuman GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing
27 May 2025 Pengumuman GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance
21 May 2025 Pengumuman GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation
20 May 2025 Pengumuman GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations
08 May 2025 Pengumuman GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025
07 May 2025 Pengumuman GeoVax Expands Gedeptin(R) Patent Portfolio
06 May 2025 Pengumuman GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production
01 May 2025 Pengumuman GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update
29 Apr 2025 Pengumuman GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting
24 Apr 2025 Pengumuman GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress
24 Apr 2025 Pengumuman GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater
23 Apr 2025 Pengumuman GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025
22 Apr 2025 Pengumuman GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations
16 Apr 2025 Pengumuman GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum
16 Apr 2025 Pengumuman GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates
15 Apr 2025 Pengumuman GeoVax to Present Clinical Data at Upcoming April Industry Events
15 Apr 2025 Pengumuman GeoVax to Present at the Emerging Growth Conference on April 16, 2025
09 Apr 2025 Pengumuman GeoVax Receives USPTO Notice of Allowance for Marburg Hemorrhagic Fever Vaccine Patent
Papar semua
1.421.421.211.211.011.010.7980.7980.5900.590Jun 17Jun 17Jun 18Jun 18Jun 20Jun 20Jun 23Jun 23Jun 24Jun 24Jun 25Jun 25Jun 26Jun 26Jun 27Jun 27

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.0400.0400.0200.0200.0000.000-0.020-0.020-0.040-0.040MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda